CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major cancer trial tests gentler chemo schedule
Disease control TerminatedThis study aims to find out if giving a common chemotherapy drug (cisplatin) weekly alongside radiation is easier for patients to tolerate than giving it every three weeks. It will also check if the weekly schedule is at least as good at helping patients live longer. The trial in…
Matched conditions: CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Can a year of Immune-Boosting drug keep throat cancer from coming back?
Disease control OngoingThis study is for people with intermediate-risk, HPV-positive throat cancer that has spread to nearby lymph nodes. After finishing standard treatment with chemotherapy and radiation, patients are randomly assigned to either receive a year of an immunotherapy drug (nivolumab) or t…
Matched conditions: CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for patients who Can't take standard chemo
Disease control OngoingThis early-stage trial is testing a new drug called peposertib combined with radiation therapy for patients with advanced head and neck cancer who cannot take the standard chemotherapy drug cisplatin. The main goals are to find the safest and most effective dose of peposertib and…
Matched conditions: CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC